Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.

European journal of cancer (Oxford, England : 1990) - 1 Feb 2018

Delahousse Julia, Verlingue Loic, Broutin Sophie, Legoupil Clémence, Touat Mehdi, Doucet Ludovic, Ammari Samy, Lacroix Ludovic, Ducreux Michel, Scoazec Jean-Yves, Malka David, Paci Angelo, Hollebecque Antoine

Abstract excerpt

Therapeutic resources are limited for advanced biliary tract cancers and prognosis remains poor. Somatic mutations in isocitrate dehydrogenase (IDH)1/2 gene are found in 5-36% of patients with intrahepatic cholangiocarcinoma (ICC). The mutant forms of IDH1/2 catalyse the non-reversible accumulation of 2-hydroxyglutarate (2HG). Increasing numbers of indirect or direct-targeted therapies are developed to IDH1/2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Cholangiocarcinoma

Share to Glutarates

Share to Isocitrate Dehydrogenase

Share to Isomerism

Share to Mutation

Source

Identifiers

PMID: 29274619
DOI: 10.1016/j.ejca.2017.11.024

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.PMID 29274619Read ↗

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma.Semantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma cells to MDM2 inhibitorsSemantic proximity Read ↗

Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.Semantic proximity Read ↗

Biology of IDH mutant cholangiocarcinoma.Semantic proximity Read ↗

IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future PerspectivesSemantic proximity Read ↗

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future TherapiesSemantic proximity Read ↗

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.Semantic proximity Read ↗

Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.